Technical Analysis for MRSN - Mersana Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
MRSN closed up 0.23 percent on Friday, March 23, 2018, on 47 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||N/A||Up||Up|
|See historical MRSN trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 23||Wide Bands||Range Expansion||0.00%|
|Mar 23||Overbought Stochastic||Strength||0.00%|
|Mar 22||Stochastic Sell Signal||Bearish||0.23%|
|Mar 22||Slingshot Bullish||Bullish Swing Setup||0.23%|
|Mar 22||Wide Bands||Range Expansion||0.23%|
|Mar 22||Overbought Stochastic||Strength||0.23%|
|Mar 21||Doji - Bearish?||Reversal||-2.20%|
|Mar 21||Wide Bands||Range Expansion||-2.20%|
|Mar 21||Overbought Stochastic||Strength||-2.20%|
|Mar 20||Wide Bands||Range Expansion||-2.31%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more MRSN news...
|52 Week High||21.01|
|52 Week Low||12.45|
|200-Day Moving Average||0.0|
|50-Day Moving Average||15.5902|
|20-Day Moving Average||16.126|
|10-Day Moving Average||16.949|
|Average True Range||1.239|
|Chandelier Exit (Long, 3 ATRs )||15.168|
|Chandelier Exit (Short, 3 ATRs )||17.287|
|Upper Bollinger Band||19.5642|
|Lower Bollinger Band||12.6878|
|Percent B (%b)||0.74|
|MACD Signal Line||0.3619|
|Market Cap||404.29 Million|
|Num Shares||22.7 Million|
|Price-to-Earnings (P/E) Ratio||-1.10|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||19.17|
|Resistance 3 (R3)||19.26||18.89||18.94|
|Resistance 2 (R2)||18.89||18.55||18.85||18.86|
|Resistance 1 (R1)||18.35||18.33||18.62||18.26||18.79|
|Support 1 (S1)||17.44||17.64||17.71||17.35||16.81|
|Support 2 (S2)||17.07||17.42||17.03||16.74|
|Support 3 (S3)||16.53||17.07||16.66|
|Support 4 (S4)||16.44|